Lin Zhuoer, Sun Ruochen, Ross Joseph S, Lau Kien, Stumpf Sophia, Chen Xi
Division of Health Policy and Administration, School of Public Health, University of Illinois Chicago.
Department of Health Care Management and Economics, The Wharton School, University of Pennsylvania.
medRxiv. 2025 May 5:2025.05.03.25326933. doi: 10.1101/2025.05.03.25326933.
Alzheimer's disease (AD) disproportionately affects racial and ethnic minoritized populations in the United States, yet these groups remain markedly underrepresented in clinical research. Phase III clinical trials are critical for informing regulatory decision and treatment guidelines, but the extent to which they report and include racial and ethnic diverse participants in the US context has not been systematically assessed.
We conducted a comprehensive retrospective review of all US-based Phase III AD clinical trials from 1997 to 2023 using the Trialtrove database, cross-referenced with PubMed, ClinicalTrials.gov, and other public sources. We analyzed long-term trends in the reporting and representation of racial and ethnic groups across the longest observation period to date.
Of 88 identified trials, 71 (80.7%) had published data. Nearly half (49.3%) did not report any race or ethnicity information. Among those that did, most focused on White patients, with limited and inconsistent reporting for racial and ethnic minoritized groups. Median enrollment was 0.9% for Asian or Pacific Islander, 4.5% for Black (ethnicity unspecified), 7.2% for Black (non-Hispanic), 5.2% for Hispanic, and 0.4% for Native American participants, compared to nearly 90% for White participants. Only 4.2% of trials conducted subgroup analysis by race or ethnicity, and none reported detailed outcome differences. Terminology varied widely and no trials acknowledged underrepresentation or proposed corrective strategies. Notably, these patterns showed little to no improvement over time.
Racial and ethnic minoritized populations remain consistently underreported and underrepresented in Phase III AD trials in the US, limiting the generalizability of findings and risking the exacerbation of health inequities. Improving equity in AD research will require standardized reporting, inclusive recruitment practices, and intentional efforts to engage underrepresented communities.
阿尔茨海默病(AD)对美国的少数族裔人群影响尤为严重,但这些群体在临床研究中的代表性仍然明显不足。III期临床试验对于为监管决策和治疗指南提供依据至关重要,但在美国背景下,它们报告和纳入不同种族和族裔参与者的程度尚未得到系统评估。
我们使用Trialtrove数据库对1997年至2023年在美国进行的所有III期AD临床试验进行了全面回顾,并与PubMed、ClinicalTrials.gov和其他公共来源进行交叉引用。我们分析了迄今为止最长观察期内不同种族和族裔群体报告和代表性的长期趋势。
在88项确定的试验中,71项(80.7%)已发表数据。近一半(49.3%)未报告任何种族或族裔信息。在报告了相关信息的试验中,大多数关注白人患者,对少数族裔群体的报告有限且不一致。亚洲或太平洋岛民参与者的中位入组率为0.9%,黑人(未指定种族)为4.5%,黑人(非西班牙裔)为7.2%,西班牙裔为5.2%,美国原住民参与者为0.4%,而白人参与者接近90%。只有4.2%的试验按种族或族裔进行了亚组分析,且没有试验报告详细的结果差异。术语差异很大,没有试验承认代表性不足或提出纠正策略。值得注意的是,随着时间的推移,这些模式几乎没有改善。
在美国的III期AD试验中,少数族裔群体的报告和代表性一直不足,这限制了研究结果的普遍性,并有可能加剧健康不平等。改善AD研究的公平性需要标准化报告、包容性的招募做法,以及有意努力让代表性不足的社区参与进来。